Iclusig (Ponatinib)

Ponatinib blocks the ATP‑binding site of the BCR‑ABL fusion protein, preventing its kinase activity even when the T315I mutation is present. By also inhibiting other kinases such as FGFR, VEGFR, PDGFR and SRC family members, it disrupts multiple signaling pathways that drive malignant cell growth, survival and angiogenesis.

The exact dose of Iclusig is determined by the prescribing physician based on the individual patient's disease characteristics, prior therapies and tolerance. Ponatinib is supplied in 15 mg and 30 mg tablets, and the prescriber selects the appropriate strength and dosing schedule for each patient.

Iclusig is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required for women of child‑bearing potential. Safety during breastfeeding has not been established, so breastfeeding is generally discouraged while on therapy.

To place an order, submit an enquiry on the Iclusig product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with earlier TKIs, ponatinib has a broader kinase inhibition profile and retains activity against the T315I mutation, which confers resistance to many other agents. This makes Iclusig a valuable option for patients who have failed prior TKIs, though its safety profile requires careful monitoring for vascular and hepatic events.

Iclusig tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Iclusig is taken orally as a whole tablet with or without food. Patients should swallow the tablet with water and follow the dosing schedule prescribed by their oncologist, who will adjust the regimen based on response and tolerability.

The most serious risks include arterial occlusive events such as heart attack or stroke, severe hypertension, pancreatitis, and hepatotoxicity manifested by marked liver enzyme elevations. Prompt recognition and management of these conditions are essential, and regular monitoring is recommended throughout treatment.

Iclusig should be avoided in patients with known hypersensitivity to ponatinib or any tablet excipients, in pregnant women, and in individuals with uncontrolled cardiovascular disease or active severe infections. Clinicians must also assess liver and pancreatic function before initiating therapy.